{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:59:51Z","timestamp":1792598391185,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s12185-021-03246-z","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T11:48:01Z","timestamp":1635248881000},"page":"585-589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Successful treatment with tirabrutinib for relapsed lymphoplasmacytic lymphoma complicated by Bing\u2013Neel syndrome"],"prefix":"10.1007","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6097-5633","authenticated-orcid":false,"given":"Masuho","family":"Saburi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Saburi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Ohtsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,26]]},"reference":[{"key":"3246_CR1","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1111\/cas.14561","volume":"111","author":"N Sekiguchi","year":"2020","unstructured":"Sekiguchi N, Rai S, Munakata W, Suzuki K, Handa H, Shibayama H, et al. A multicenter, open-label, phase II study of tirabrutinib (ONO\/GS-4059) in patients with Waldenstr\u00f6m\u2019s macroglobulinemia. Cancer Sci. 2020;111:3327\u201337.","journal-title":"Cancer Sci"},{"key":"3246_CR2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/neuonc\/noaa145","volume":"23","author":"Y Narita","year":"2021","unstructured":"Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, et al. Phase I\/II study of tirabrutinib, a second-generation Bruton\u2019s tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma. Neuro Oncol. 2021;23:122\u201333.","journal-title":"Neuro Oncol"},{"key":"3246_CR3","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s11060-009-9968-3","volume":"96","author":"RG Malkani","year":"2010","unstructured":"Malkani RG, Tallman M, Gottardi-Littell N, Karpus W, Marszalek L, Variakojis D, et al. Bing\u2013Neel syndrome: an illustrative case and a comprehensive review of the published literature. J Neurooncol. 2010;96:301\u201312.","journal-title":"J Neurooncol"},{"key":"3246_CR4","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.3324\/haematol.2015.133744","volume":"100","author":"L Simon","year":"2015","unstructured":"Simon L, Fitsiori A, Lemal R, Dupuis J, Carpentier B, Boudin L, et al. Bing\u2013Neel syndrome, a rare complication of Waldenstr\u00f6m macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO). Haematologica. 2015;100:1587\u201394.","journal-title":"Haematologica"},{"key":"3246_CR5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/bjh.13883","volume":"172","author":"JJ Castillo","year":"2016","unstructured":"Castillo JJ, D\u2019Sa S, Lunn MP, Minnema MC, Tedeschi A, Lansigan F, et al. Central nervous system involvement by Waldenstr\u00f6m macroglobulinaemia (Bing\u2013Neel syndrome): a multi-institutional retrospective study. Br J Haematol. 2016;172:709\u201315.","journal-title":"Br J Haematol"},{"key":"3246_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3324\/haematol.2016.147728","volume":"102","author":"MC Minnema","year":"2017","unstructured":"Minnema MC, Kimby E, D\u2019Sa S, Fornecker LM, Poulain S, Snijders TJ, et al. Guideline for the diagnosis, treatment and response criteria for Bing\u2013Neel syndrome. Haematologica. 2017;102:43\u201351.","journal-title":"Haematologica"},{"key":"3246_CR7","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood"},{"key":"3246_CR8","doi-asserted-by":"publisher","first-page":"5090","DOI":"10.1182\/blood.V122.21.5090.5090","volume":"122","author":"T Kulkarni","year":"2013","unstructured":"Kulkarni T, Treon SP, Manning RA, Xu L, Rinne M, Lee EQ, et al. Clinical characteristics and treatment outcome of CNS involvement (Bing\u2013Neel syndrome) in Waldenstroms macroglobulinemia. Blood. 2013;122:5090.","journal-title":"Blood"},{"key":"3246_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.clineuro.2018.02.008","volume":"167","author":"K Vermeiren","year":"2018","unstructured":"Vermeiren K, Lemmerling M, Louagie H, Vantomme M, Petrick M, Bouttens F, et al. Bing\u2013Neel syndrome presenting as gait problems due to spinal cord involvement. Clin Neurol Neurosurg. 2018;167:59\u201361.","journal-title":"Clin Neurol Neurosurg"},{"key":"3246_CR10","doi-asserted-by":"publisher","first-page":"E17","DOI":"10.1002\/ajh.24279","volume":"91","author":"A Cabannes-Hamy","year":"2016","unstructured":"Cabannes-Hamy A, Lemal R, Goldwirt L, Poulain S, Amorim S, P\u00e9rignon R, et al. Efficacy of ibrutinib in the treatment of Bing\u2013Neel syndrome. Am J Hematol. 2016;91:E17\u20139.","journal-title":"Am J Hematol"},{"key":"3246_CR11","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1080\/10428194.2018.1441409","volume":"59","author":"L Boudin","year":"2018","unstructured":"Boudin L, Patient M, Rom\u00e9o E, Blad\u00e9 JS, de Jaur\u00e9guiberry JP. Efficacy of ibrutinib as first-line treatment of tumoral Bing\u2013Neel syndrome. Leuk Lymphoma. 2018;59:2746\u20138.","journal-title":"Leuk Lymphoma"},{"key":"3246_CR12","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/bjh.14218","volume":"179","author":"C Mason","year":"2017","unstructured":"Mason C, Savona S, Rini JN, Castillo JJ, Xu L, Hunter ZR, et al. Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome. Br J Haematol. 2017;179:339\u201341.","journal-title":"Br J Haematol"},{"key":"3246_CR13","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMoa1200710","volume":"367","author":"SP Treon","year":"2012","unstructured":"Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P somatic mutation in Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med. 2012;367:826\u201333.","journal-title":"N Engl J Med"},{"key":"3246_CR14","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1182\/blood-2012-12-475111","volume":"122","author":"G Yang","year":"2013","unstructured":"Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning RJ, et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstr\u00f6m macroglobulinemia. Blood. 2013;122:1222\u201332.","journal-title":"Blood"},{"key":"3246_CR15","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/leu.2016.8","volume":"30","author":"KV Argyropoulos","year":"2016","unstructured":"Argyropoulos KV, Vogel R, Ziegler C, Altan-Bonnet G, Velardi E, Calafiore M, et al. Clonal B cells in Waldenstr\u00f6m\u2019s macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling. Leukemia. 2016;30:1116\u201325.","journal-title":"Leukemia"},{"key":"3246_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41408-020-0277-6","volume":"10","author":"M Munshi","year":"2020","unstructured":"Munshi M, Liu X, Chen JG, Xu L, Tsakmaklis N, Demos MG, et al. SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. Blood Cancer J. 2020;10:12.","journal-title":"Blood Cancer J"},{"key":"3246_CR17","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","volume":"372","author":"SP Treon","year":"2015","unstructured":"Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med. 2015;372:1430\u201340.","journal-title":"N Engl J Med"},{"key":"3246_CR18","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1200\/JCO.2018.78.6426","volume":"36","author":"SP Treon","year":"2018","unstructured":"Treon SP, Gustine J, Meid K, Yang G, Xu L, Liu X, et al. Ibrutinib monotherapy in symptomatic, treatment-na\u00efve patients with Waldenstr\u00f6m macroglobulinemia. J Clin Oncol. 2018;36:2755\u201361.","journal-title":"J Clin Oncol"},{"key":"3246_CR19","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1182\/blood-2015-05-647834","volume":"126","author":"S Bernard","year":"2015","unstructured":"Bernard S, Goldwirt L, Amorim S, Brice P, Bri\u00e8re J, de Kerviler E, et al. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. Blood. 2015;126:1695\u20138.","journal-title":"Blood"},{"key":"3246_CR20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/bjh.14122","volume":"178","author":"DL Tucker","year":"2017","unstructured":"Tucker DL, Naylor G, Kruger A, Hamilton MS, Follows G, Rule SA. Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement\u2014a multi-centre case series from the United Kingdom. Br J Haematol. 2017;178:327\u20139.","journal-title":"Br J Haematol"},{"key":"3246_CR21","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1182\/blood-2016-02-697193","volume":"127","author":"A Wanquet","year":"2016","unstructured":"Wanquet A, Birsen R, Lemal R, Hunault M, Leblond V, Aurran-Schleinitz T. Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia. Blood. 2016;127:2356\u20138.","journal-title":"Blood"},{"key":"3246_CR22","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1097\/HS9.0000000000000155","volume":"2","author":"J Wong","year":"2018","unstructured":"Wong J, Cher L, Griffiths J, Cohen A, Huang J, Wang L, et al. Efficacy of zanubrutinib in the treatment of Bing\u2013Neel syndrome. Hemasphere. 2018;2:e155.","journal-title":"Hemasphere"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03246-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-021-03246-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03246-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T19:03:52Z","timestamp":1648667032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-021-03246-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,26]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["3246"],"URL":"https:\/\/doi.org\/10.1007\/s12185-021-03246-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,26]]},"assertion":[{"value":"12 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}